SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
Semin Hematol
; 59(4): 192-197, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-2323456
ABSTRACT
Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Humans
Language:
English
Journal:
Semin Hematol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS